Insights about second-line treatment options for metastatic melanoma and discusses available data for treatment sequencing.
Case: A 62-Year-Old Female with Stage IV Melanoma
This is a video synopsis/summary of a Case-Based Peer Perspective, featuring Michael B. Atkins, MD.
For this patient progressing after first-line nivolumab plus ipilimumab, next treatment would undoubtedly be a BRAF/MEK inhibitor combination. The improved outcomes with immunotherapy first in the DREAMseq trial (NCT02224781) relate to 3 key factors: (1) longer duration of response to immunotherapy; (2) more CNS progressions on targeted therapy; and (3) BRAF/MEK inhibitors retain efficacy second-line after immunotherapy progression, whereas second-line immunotherapy is less effective following targeted therapy.
Targeted therapy is a critical component of the optimal treatment sequence following initial immunotherapy. BRAF/MEK inhibitors work as well second line as first line, overcoming the relatively poor second-line immunotherapy responses after disease progression on targeted therapy.
Video synopsis is AI-generated and reviewed by Targeted Oncology® editorial staff.
RELATIVITY-047 Vs CheckMate 067 Matched Cohorts in Melanoma Show Similar Efficacy
October 10th 2024During a Case-Based Roundtable® event, Ahmad Tarhini, MD, PhD, discussed the indirect comparison of ipilimumab plus nivolumab and nivolumab/relatlimab in advanced melanoma in the second article of a 2-part series.
Read More